Arena Pharmaceuticals Announces New Strategic Focus and Cost Reduction Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Arena Pharma (ARNA) Announces Cost-Reduction Program; Will Trim U.S. Headcount by 35%
October 27, 2015 4:01 PM EDTArena Pharma (NASDAQ: ARNA) announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its research and development priorities.
Arena intends to focus on its key strengths by concentrating near-term activities and resources primarily on:
advancing its APD334 program, including the ongoing Phase 2 clinical trial for ulcerative colitis, and potentially exploring additional indications beyond inflammatory bowel disease through small pilot studies;advancing its ralinepag (formerly known as APD811) program, including its ongoing Phase 2 clinical trial for pulmonary arterial hypertension (PAH), and potentially... More